6.2 Organophosphate, Paracetamol & Snakebite Toxicology

Organophosphate, Paracetamol & Snakebite Toxicology

Toxico-emergencies represent one of the most high-yielding areas of emergency medicine in UPSC CMS examinations. Command over antidote mechanisms, toxicodynamics, clinical endpoints of therapy, and bedside testing is crucial for solving clinical vignettes.

---

1. Organophosphate & Carbamate Insecticide Poisoning

Organophosphate (OP) compounds (e.g., Malathion, Parathion, Chlorpyrifos, Dichlorvos) are widely used agricultural insecticides in India and represent a common cause of accidental and intentional self-poisoning.

Pathophysiology

Organophosphates inhibit the enzyme Acetylcholinesterase (AChE) by phosphorylating its active esteratic site. This causes toxic accumulation of acetylcholine (ACh) at parasympathetic postganglionic junctions (muscarinic), neuromuscular junctions (nicotinic), and central nervous system synapses. Over time (hours to days), the enzyme-poison complex undergoes "aging" (dealkylation), making the AChE inhibition permanent and resistant to reactivating oximes.

Clinical Features: The Cholinergic Toxidrome

• Muscarinic Effects (DUMBELS):
  • D: Diarrhea / Diaphoresis
  • U: Urination
  • M: Miosis (pinpoint pupils)
  • B: Bronchorrhea & Bronchospasm (Primary cause of death due to asphyxiation and pulmonary edema)
  • E: Emesis
  • L: Lacrimation
  • S: Salivation
• Nicotinic Effects (MTWThF): Muscle fasciculations (tongue, eyelids, chest wall), Tachycardia, Weakness, Hypertension, and flaccid Paralysis.
• Central Nervous System: Confusion, agitation, seizures, central respiratory depression, coma.

Complications Delayed in Time

1. Intermediate Syndrome (IMS): Occurs 24 to 96 hours post-exposure following initial recovery from cholinergic crisis. Caused by persistent dysfunction at neuromuscular junctions. Characterized by weakness of neck flexors, proximal limb muscles, cranial nerve-innervated muscles, and respiratory muscles leading to sudden respiratory failure. Requires mechanical ventilation.
2. Organophosphate-Induced Delayed Polyneuropathy (OPIDN): Occurs 2 to 3 weeks after exposure due to inhibition of Neuropathy Target Esterase (NTE). Manifests as a distal, symmetrical sensory-motor peripheral neuropathy ("foot drop" and stocking-glove sensory loss).

Emergency Management Protocol

1. Decontamination & Resuscitation: Remove all contaminated clothing; wash skin thoroughly with soap and water. Secure airway and administer oxygen. Perform gastric lavage ONLY after airway is protected by endotracheal intubation.
2. Antidote #1 — Atropine (Competitive Muscarinic Antagonist):
   • Dose: Initial IV bolus of 1.8 to 3.0 mg (or 2–5 mg IV). Double the dose every 5 to 10 minutes if no response.
   • Endpoints of Atropinization:
     • Clear chest on auscultation (disappearance of bronchorrhea and pulmonary crepitations) — MOST IMPORTANT CLINICAL ENDPOINT!
     • Heart Rate > 80–100 beats/min
     • Systolic BP > 90 mmHg
     • Dry skin and axillae
     • Pupils mid-dilated or dilated (Note: pupil size alone is NOT a reliable endpoint!).
   • Maintenance: Once atropinized, start continuous IV atropine infusion at 10–20% of the total dose required for initial atropinization per hour.
3. Antidote #2 — Oximes (Pralidoxime / 2-PAM):
   • Mechanism: Nucleophilic reactivators of phosphorylated acetylcholinesterase before aging occurs. Effective against nicotinic signs (muscle fasciculations and weakness).
   • Dose: Loading dose of 1 to 2 g IV in 100 mL Normal Saline over 30 minutes, followed by continuous IV infusion of 500 mg/hour.
4. Contraindications: Avoid Morphine, Aminophylline, Succinylcholine, and Phenothiazines.

---

2. Paracetamol (Acetaminophen) Hepatotoxicity

Paracetamol is a benign analgesic at therapeutic doses (max 4 g/day in adults) but causes severe, acute centrilobular hepatic necrosis in overdose (> 150 mg/kg or > 7.5–10 g single ingestion).

Pathophysiology & Toxicokinetics

• At therapeutic doses, 90% of paracetamol undergoes phase II hepatic conjugation via glucuronidation and sulfation into non-toxic, water-soluble metabolites excreted in urine.
• ~5–10% is metabolized by the cytochrome P450 enzyme CYP2E1 into N-acetyl-p-benzoquinone imine (NAPQI), a highly toxic, electrophilic intermediate.
• Under normal conditions, NAPQI is immediately detoxified by conjugation with endogenous hepatic Glutathione to form non-toxic mercapturic acid.
• In paracetamol overdose, the glucuronidation and sulfation pathways become saturated. Excess paracetamol is shunted to CYP2E1, generating massive amounts of NAPQI that deplete hepatic glutathione stores by > 70–80%.
• Unbound NAPQI covalently binds to cysteine sulfhydryl groups on hepatocellular proteins, causing mitochondrial dysfunction, oxidative stress, and centrilobular (Zone 3) hepatic necrosis.

Stages of Paracetamol Poisoning

• Stage I (0–24 hours): Anorexia, nausea, vomiting, diaphoresis, malaise. LFTs are normal.
• Stage II (24–72 hours): Subclinical onset of hepatotoxicity. Right upper quadrant abdominal pain and hepatomegaly. AST and ALT rise rapidly (often > 1,000–10,000 U/L), along with elevation of PT/INR and bilirubin.
• Stage III (72–96 hours): Peak hepatotoxicity. Jaundice, marked coagulopathy, hepatic encephalopathy, hypoglycemia, lactic acidosis, and acute kidney injury (acute tubular necrosis).
• Stage IV (4–14 days): Recovery phase for survivors, with complete histological resolution over weeks.

Management & Antidote Protocol

1. Activated Charcoal: 1 g/kg orally if patient presents within 1 to 2 hours of ingestion.
2. Rumack-Matthew Nomogram: Used for acute single ingestions. Obtain serum paracetamol concentration at least 4 hours post-ingestion. Plot the level on the nomogram:
   • Treatment line starts at 150 mcg/mL (1000 umol/L) at 4 hours (or 37.5 mcg/mL at 12 hours).
   • If the level lies on or above the treatment line, initiate antidote therapy immediately.
3. Specific Antidote — N-Acetylcysteine (NAC):
   • Mechanism: Precursor for glutathione synthesis; directly combines with NAPQI; acts as an antioxidant and anti-inflammatory agent improving microvascular perfusion.
   • Efficacy: Almost 100% protective against severe hepatotoxicity when administered within 8 hours of acute ingestion.
   • Oral Protocol (Prescott): 140 mg/kg loading dose, followed by 70 mg/kg every 4 hours for 17 maintenance doses (total 72-hour regimen).
   • IV Protocol (3-Stage 20-Hour Infusion):
     • 150 mg/kg in 200 mL 5% Dextrose over 1 hour.
     • 50 mg/kg in 500 mL 5% Dextrose over 4 hours.
     • 100 mg/kg in 1000 mL 5% Dextrose over 16 hours (Total dose: 300 mg/kg).

3. Snakebite Toxicology in India

Snakebite envenomation is a significant neglected tropical disease causing high mortality in rural India. The vast majority of fatal bites are caused by the "Big Four" venomous snake species:

---

Clinical Presentation & Syndromes

A. Neurotoxic Envenomation (Elapid Bites)

• Cobra & Krait: Venom toxins disrupt acetylcholine transmission at the neuromuscular junction.
• Earliest Clinical Sign: Bilateral Ptosis (drooping of eyelids) and external ophthalmoplegia.
• Progression: Descending paralysis involving facial muscles, dysarthria, dysphagia, pooling of secretions, weakness of neck flexors, and finally flaccid paralysis of intercostal muscles and diaphragm leading to respiratory arrest.
• Krait Specifics: Bites frequently occur at night while victim is sleeping on the floor. The bite is virtually painless with minimal local swelling. Patients present with severe paroxysmal abdominal pain (colic) followed by morning neuroparalysis.
• Neostigmine Challenge Test: Cobra venom contains post-synaptic neurotoxins (alpha-neurotoxins) that reversibly block nicotinic ACh receptors. Patients with Cobra bites show dramatic improvement with Neostigmine (0.5–2.5 mg IV) plus Atropine (0.6 mg IV). Krait venom contains pre-synaptic neurotoxins (beta-bungarotoxin) which destroy nerve terminals, making them unresponsive to Neostigmine; mechanical ventilation is crucial.

B. Vasculotoxic / Hemotoxic Envenomation (Viper Bites)

• Viperidae Venom: Contains hemorrhagins, zinc metalloproteinases, and procoagulant enzymes (prothrombin and Factor X activators) that consume fibrinogen and platelets.
• Local Features: Severe rapidly progressive swelling, erythema, severe pain, blistering, necrotic bullae, and compartment syndrome.
• Systemic Features: Spontaneous systemic bleeding (gingival bleeding, epistaxis, hematemesis, melena, hematuria, hemoptysis, intracranial hemorrhage), hypotension, acute kidney injury (due to acute tubular necrosis or cortical necrosis in Russell's viper), and Disseminated Intravascular Coagulation (DIC).

---

Bedside Diagnostic Test: 20-Minute Whole Blood Clotting Test (20WBCT)

The 20WBCT is the single most reliable bedside screening test for venom-induced consumption coagulopathy in viperine bites:

1. Take 2 mL of fresh venous blood drawn from an un-infused vein.
2. Place into a clean, dry, un-siliconized glass test tube.
3. Leave undisturbed for 20 minutes at ambient room temperature.
4. Incline the tube gently.
   • Normal Result (Clotted): Blood has formed a firm clot.
   • Positive Result (Incomplete / Non-Clotting): Blood remains completely liquid. Indicates severe hypofibrinogenemia (< 50 mg/dL) due to hemotoxic envenomation — Mandatory indication for Anti-Snake Venom (ASV).

---

Polyvalent Anti-Snake Venom (ASV) Protocol

In India, Polyvalent ASV is produced by hyper-immunizing horses against the venom of all Big Four species (Cobra, Krait, Russell's Viper, Saw-scaled Viper).

Indications for ASV

• Systemic Envenomation:
  • Neurotoxic signs (ptosis, diplopia, respiratory distress).
  • Hemotoxic signs (positive 20WBCT, spontaneous systemic bleeding).
  • Cardiovascular collapse, shock, or arrhythmias.
  • Acute Kidney Injury / hemoglobinuria / myoglobinuria.
• Severe Local Envenomation: Rapidly spreading swelling involving more than half of the bitten limb within 3–4 hours.

Dosing & Administration

• Initial Loading Dose: 10 vials (100 mL) of reconstituted polyvalent ASV.
• Method of Administration: Reconstitute each vial in 10 mL of sterile water. Dilute the 10 vials (100 mL) in 240–500 mL of 0.9% Normal Saline or 5% Dextrose. Infuse intravenously over 1 hour (start slow at 1–2 mL/min for first 10 minutes while observing for anaphylaxis).
• Local Injection: NEVER inject ASV locally into the bite site or ring-block the finger/toe.
• Repeat Doses:
  • Hemotoxic Bites: Re-assess 20WBCT after 6 hours. If blood remains non-clotting, repeat 5 to 10 vials of ASV. Repeat every 6 hours until clotting is restored.
  • Neurotoxic Bites: If neuroparalysis worsens or fails to improve after 1 to 2 hours, administer a second dose of 10 vials of ASV.
• ASV Reaction Management: If severe anaphylactoid reaction occurs during infusion, temporarily stop ASV, administer Adrenaline 0.5 mg IM, IV Hydrocortisone, and Chlorpheniramine. Resume ASV at a slower rate once reaction resolves.